Virtu Financial’s Galmed Pharmaceuticals GLMD Stock Holding History

Virtu Financial’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,126	Closed	-$16K	–	1678
2025 Q1	$16K	Buy	+11,126	New	+$27.4K	﹤0.01%	1134
2023 Q4	–	Sell	-2,467	Closed	-$18K	–	1721
2023 Q3	$18K	Buy	+2,467	New	+$32.7K	﹤0.01%	1030
2023 Q2	–	Sell	-176	Closed	-$13K	–	1699
2023 Q1	$13K	Buy	+176	New	+$18.9K	﹤0.01%	1315
2022 Q4	–	Sell	-125	Closed	-$7K	–	1819
2022 Q3	$7K	Buy	+125	New	+$10.7K	﹤0.01%	1550
2022 Q1	–	Sell	-200	Closed	-$65K	–	1686
2021 Q4	$65K	Buy	+200	New	+$90.3K	0.01%	1265
2020 Q3	–	Sell	-83	Closed	-$71K	–	1238
2020 Q2	$71K	Buy	+83	New	+$70K	0.01%	948
2018 Q3	–	Sell	-78	Closed	-$166K	–	1783
2018 Q2	$166K	Buy	+78	New	+$113K	0.01%	1554

Other funds holding GLMD

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Virtu Financial's GLMD Position: Q2 2025 in Review

Virtu Financial sold out of Galmed Pharmaceuticals (GLMD) in Q2 2025, closing a stake of 11,126 shares — an estimated $16K sold.

Virtu Financial first reported a position in GLMD in Q2 2018 and held it in 7 quarters. The position peaked at $166K in Q2 2018. 15 funds tracked by Wall St. Rank hold GLMD as of Q2 2025.

Virtu Financial reported no remaining Galmed Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Virtu Financial sold 11,126 Galmed Pharmaceuticals shares in Q2 2025, an estimated $16K.
Virtu Financial first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Virtu Financial's Galmed Pharmaceuticals position peaked at $166K in Q2 2018.
15 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.